Patrick M R, Kirkham B W, Graham M, Harrision L C
Burnet Clinical Research Unit, Walter and Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Parkville, Australia.
J Rheumatol. 1995 Apr;22(4):654-8.
To investigate whether circulating levels of interleukin 1 beta (IL-1 beta) or soluble interleukin 2 receptor (sIL-2R) reflect clinical disease status and response to therapy in scleroderma.
Plasma IL-1 beta and serum sIL-2R were measured by ELISA in 19 patients with limited cutaneous scleroderma (9 with extraesophageal internal organ involvement), 5 patients with diffuse cutaneous scleroderma and internal organ involvement, and 11 healthy controls, as well as serially over 12 months in 4 patients with scleroderma treated with cyclosporine.
IL-1 beta levels were similar in scleroderma and control subject groups. sIL-2R levels were significantly higher in subjects with scleroderma involving internal organs (elevated in 93%), and correlated with erythrocyte sedimentation rate. sIL-2R levels decreased over 12 months in 2 of 4 patients taking cyclosporine in whom other variables remained unchanged.
Elevated serum sIL-2R is a marker of internal organ involvement in scleroderma and warrants further investigation in assessing disease prognosis and response to therapy.
研究白细胞介素1β（IL-1β）或可溶性白细胞介素2受体（sIL-2R）的循环水平是否反映硬皮病的临床疾病状态及对治疗的反应。
采用酶联免疫吸附测定法（ELISA）检测19例局限性皮肤型硬皮病患者（9例有食管外内脏受累）、5例弥漫性皮肤型硬皮病伴内脏受累患者及11名健康对照者的血浆IL-1β和血清sIL-2R水平，并对4例接受环孢素治疗的硬皮病患者在12个月内进行连续检测。
硬皮病组和对照组的IL-1β水平相似。内脏受累的硬皮病患者sIL-2R水平显著升高（93%升高），且与红细胞沉降率相关。4例服用环孢素的患者中有2例sIL-2R水平在12个月内下降，而其他变量保持不变。
血清sIL-2R升高是硬皮病内脏受累的一个标志物，在评估疾病预后和治疗反应方面值得进一步研究。
